This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part two of her interview, Amber Hill, PhD, founder and CEO of Research Grid, identified the administrative back-office processes causing the most friction in Phase I trials. Purpose-built, traceable AI models designed for regulatory environments are the right tool for addressing them, with the biggest early wins in scheduling, protocol compliance monitoring, and data reconciliation.
- In a new contributed article, Deborah Phippard, PhD, chief scientific officer of Precision for Medicine, addressed how sponsors can build lean but robust early-phase evidence packages when investors demand patient-level data as it emerges. Without biological context, two responders and two nonresponders do not establish a trend, and biobanked samples retained prospectively allow teams to investigate outliers or rescue ambiguous datasets at modest incremental cost.
- Syneos Health announced three AI platform partnerships expanding its clinical development capabilities, including integrations with Causaly for evidence-based protocol strategy, Databricks for near-real-time operational data reducing source-to-insight time from days to hours, and Microsoft for workflow automation. Together, the partnerships are designed to create a unified intelligence environment connecting operational, clinical, and real-world data across the development lifecycle.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
